HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS)

HC Wainwright reissued their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $7.00 target price on the stock.

Several other equities analysts have also issued reports on PYXS. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a research report on Thursday, September 19th. Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price target for the company. Stephens initiated coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price target for the company. Finally, William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Pyxis Oncology has an average rating of “Moderate Buy” and an average target price of $10.00.

Pyxis Oncology Stock Performance

Shares of PYXS traded down $0.18 during trading hours on Thursday, hitting $1.92. The company had a trading volume of 1,263,399 shares, compared to its average volume of 721,072. The firm has a fifty day moving average price of $3.68 and a 200-day moving average price of $3.63. The stock has a market capitalization of $114.18 million, a price-to-earnings ratio of -2.07 and a beta of 1.27. Pyxis Oncology has a 52-week low of $1.35 and a 52-week high of $6.85.

Institutional Trading of Pyxis Oncology

Several hedge funds have recently modified their holdings of the company. Ikarian Capital LLC purchased a new stake in shares of Pyxis Oncology during the 1st quarter worth approximately $7,082,000. Vanguard Group Inc. raised its holdings in shares of Pyxis Oncology by 7.3% during the 1st quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock worth $5,970,000 after acquiring an additional 94,740 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Pyxis Oncology by 125.3% during the 2nd quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after acquiring an additional 743,499 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Pyxis Oncology by 5.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after acquiring an additional 57,016 shares in the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of Pyxis Oncology during the 2nd quarter worth approximately $3,462,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.